Pennant Investors
Latest statistics and disclosures from Pennant Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMZN, TDG, AR, MSFT, MU, and represent 58.38% of Pennant Investors's stock portfolio.
- Added to shares of these 10 stocks: SATS (+$31M), AAPL (+$27M), ENOV (+$25M), AR (+$6.4M), PRM (+$5.2M), FGEN, ARQT, ALT, FATE, NRIX.
- Started 33 new stock positions in ALLO, ARCT, Retrophin Inc note 2.500% 9/1, CMPX, BLUE, ZNTL, CHRS, QURE, ENOV, ALVR.
- Reduced shares in these 4 stocks: GOOGL (-$27M), , AMZN (-$9.4M), MSFT (-$7.2M).
- Sold out of its position in DISH Network.
- Pennant Investors was a net buyer of stock by $43M.
- Pennant Investors has $404M in assets under management (AUM), dropping by 45.82%.
- Central Index Key (CIK): 0001759176
Tip: Access up to 7 years of quarterly data
Positions held by Pennant Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Pennant Investors
Pennant Investors holds 44 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amazon (AMZN) | 13.2 | $53M | -14% | 296k | 180.38 |
|
| TransDigm Group Incorporated (TDG) | 12.8 | $52M | 42k | 1231.60 |
|
|
| Antero Res Call Option (AR) | 11.7 | $47M | +15% | 1.6M | 29.00 |
|
| Microsoft Corporation (MSFT) | 11.7 | $47M | -13% | 112k | 420.72 |
|
| Micron Technology (MU) | 8.9 | $36M | 306k | 117.89 |
|
|
| Echostar Corp Cl A (SATS) | 7.6 | $31M | NEW | 2.2M | 14.25 |
|
| Alphabet Cap Stk Cl A (GOOGL) | 7.4 | $30M | -46% | 199k | 150.93 |
|
| Apple Put Option (AAPL) | 6.8 | $27M | NEW | 160k | 171.48 |
|
| Colfax Corp (ENOV) | 6.2 | $25M | NEW | 400k | 62.45 |
|
| ODP Corp. (ODP) | 5.3 | $21M | 400k | 53.05 |
|
|
| Perimeter Solutions Sa Common Stock (PRM) | 4.2 | $17M | +43% | 2.3M | 7.42 |
|
| Fibrogen (FGEN) | 0.4 | $1.8M | NEW | 768k | 2.35 |
|
| Arcutis Biotherapeutics (ARQT) | 0.4 | $1.7M | NEW | 171k | 9.91 |
|
| Altimmune Com New (ALT) | 0.3 | $1.1M | NEW | 110k | 10.18 |
|
| Fate Therapeutics (FATE) | 0.3 | $1.1M | NEW | 146k | 7.34 |
|
| Nurix Therapeutics (NRIX) | 0.2 | $835k | NEW | 57k | 14.70 |
|
| Macrogenics (MGNX) | 0.2 | $645k | NEW | 44k | 14.72 |
|
| Igm Biosciences (IGMS) | 0.2 | $626k | NEW | 65k | 9.65 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $613k | NEW | 35k | 17.46 |
|
| Allogene Therapeutics (ALLO) | 0.1 | $574k | NEW | 128k | 4.47 |
|
| 89bio (ETNB) | 0.1 | $518k | NEW | 45k | 11.64 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $511k | NEW | 32k | 15.76 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.1 | $448k | NEW | 24k | 18.88 |
|
| Arcturus Therapeutics Hldg I (ARCT) | 0.1 | $442k | NEW | 13k | 33.77 |
|
| Agios Pharmaceuticals (AGIO) | 0.1 | $442k | NEW | 15k | 29.24 |
|
| Travere Therapeutics Note 2.500% 9/1 | 0.1 | $430k | NEW | 56k | 7.71 |
|
| Getaround (GETR) | 0.1 | $414k | 1.3M | 0.31 |
|
|
| Zymeworks Del (ZYME) | 0.1 | $407k | NEW | 39k | 10.52 |
|
| Coherus Biosciences (CHRS) | 0.1 | $402k | NEW | 168k | 2.39 |
|
| Compass Therapeutics (CMPX) | 0.1 | $394k | NEW | 199k | 1.98 |
|
| Relay Therapeutics (RLAY) | 0.1 | $352k | NEW | 42k | 8.30 |
|
| Erasca (ERAS) | 0.1 | $342k | NEW | 166k | 2.06 |
|
| Sage Therapeutics (SAGE) | 0.1 | $328k | NEW | 18k | 18.74 |
|
| Novavax Com New (NVAX) | 0.1 | $288k | NEW | 60k | 4.78 |
|
| Agenus Com New (AGEN) | 0.1 | $272k | NEW | 470k | 0.58 |
|
| Uniqure Nv SHS (QURE) | 0.1 | $252k | NEW | 49k | 5.20 |
|
| Replimune Group (REPL) | 0.1 | $249k | NEW | 31k | 8.17 |
|
| Bioxcel Therapeutics (BTAI) | 0.1 | $237k | NEW | 84k | 2.82 |
|
| Allakos (ALLK) | 0.1 | $235k | NEW | 186k | 1.26 |
|
| Seres Therapeutics (MCRB) | 0.1 | $226k | NEW | 292k | 0.77 |
|
| Allovir (ALVR) | 0.0 | $163k | NEW | 216k | 0.75 |
|
| Airspan Networks Holdings (MIMO) | 0.0 | $118k | 1.0M | 0.11 |
|
|
| Bluebird Bio (BLUE) | 0.0 | $112k | NEW | 87k | 1.28 |
|
| Grab Holdings *w Exp 99/99/999 (GRABW) | 0.0 | $16k | 80k | 0.20 |
|
Past Filings by Pennant Investors
SEC 13F filings are viewable for Pennant Investors going back to 2018
- Pennant Investors 2024 Q1 filed May 15, 2024
- Pennant Investors 2023 Q3 filed Nov. 14, 2023
- Pennant Investors 2023 Q2 filed Aug. 14, 2023
- Pennant Investors 2023 Q1 filed May 15, 2023
- Pennant Investors 2022 Q4 filed Feb. 14, 2023
- Pennant Investors 2022 Q3 filed Nov. 14, 2022
- Pennant Investors 2022 Q2 filed Aug. 15, 2022
- Pennant Investors 2022 Q1 filed May 16, 2022
- Pennant Investors 2021 Q4 filed Feb. 14, 2022
- Pennant Investors 2021 Q3 filed Nov. 15, 2021
- Pennant Investors 2021 Q2 filed Aug. 16, 2021
- Pennant Investors 2021 Q1 filed May 17, 2021
- Pennant Investors 2020 Q4 filed Feb. 16, 2021
- Pennant Investors 2020 Q3 filed Nov. 16, 2020
- Pennant Investors 2020 Q2 filed Aug. 14, 2020
- Pennant Investors 2020 Q1 filed May 15, 2020